Press Releases

The India pharmaceutical market is entering one of its most transformative phases. Valued at USD 53.29 billion in 2025, the market is forecast to reach USD 92.32 billion by 2030, growing at an impressive 11.62% CAGR.

This growth is not only about numbers—it reflects how India’s pharma industry is expanding its role in global healthcare supply chains, strengthening domestic capabilities, and aligning with sustainable manufacturing practices.

Download Free PDF Brochure - https://www.marknteladvisors.com/query/request-sample/pharmaceutical-market-india.html

What’s Driving Growth in India’s Pharma Industry?

1. Chronic Disease Burden

• India has more than 100 million people with diabetes and cardiovascular diseases account for over 25% of annual deaths.
• The country also records the highest TB prevalence in the world, contributing nearly 30% of global cases.
• These figures highlight why the demand for prescription drugs and advanced therapies is accelerating.

2. Global Trust in Indian Pharma Exports

• Indian pharmaceuticals, including generics, vaccines, and biosimilars, are exported to 200+ countries such as the US, UK, Europe, and Africa.
• Compliance with WHO and USFDA regulations has positioned India as a trusted supplier of affordable medicines.

3. Government Support & Policy Push

• Policies like Pharma Vision 2020 and the Production Linked Incentive (PLI) scheme are helping India reduce import dependency on APIs (Active Pharmaceutical Ingredients) while scaling local production.
• The India-UK Free Trade Agreement (2025) allowed pharma exports at 0% tariffs, widening India’s global reach.

Market Opportunities: Why the Outlook Looks Bright

• Pharma Exports on the Rise: Growing demand for low-cost generics and biosimilars in regulated markets offers a big window for expansion.
• PLI Scheme Investments: Nearly USD 800 million has been allocated to scale API and drug manufacturing, reducing reliance on imports.
• R&D Incentives: The government reintroduced 200% tax deductions on R&D expenses, encouraging innovation in specialty drugs, biologics, and next-gen therapies.
• Vision 2030 Alignment: India’s push towards sustainable, digital-first, and export-driven pharma manufacturing aligns with its long-term economic and healthcare goals.

Challenges Hindering Growth

While the outlook is positive, the industry faces several barriers:

• Regulatory Hurdles: Agencies like CDSCO enforce strict approval standards, leading to long and complex compliance processes.
• Intense Competition in Generics: Small and medium-scale companies face thin margins and struggle to compete with big pharma players with wider networks and deeper pockets.
• High Pricing Pressure: The global generic drugs market is highly price-sensitive, limiting profitability for Indian manufacturers.

India Pharma Market Trends (2025–2030)

Sustainable Manufacturing

• Companies such as Lupin, Sun Pharma, and Granules India are investing in green chemistry, renewable energy, and eco-friendly pharma zones.
• These practices not only align with environmental goals but also improve long-term cost efficiency.

Biologics & Biosimilars Growth

• Biosimilars are emerging as the next big growth engine, especially in oncology and immunotherapy.
• Partnerships like Dr. Reddy’s & Alvotech (2025) to develop a biosimilar of Keytruda highlight this trend.

Digital & AI Adoption

• The use of AI, IoT, and data analytics is making supply chains smarter, reducing wastage, and improving drug discovery.

Market Segmentation Highlights:

By Product Type:

• Prescription drugs dominate with a 70% share, driven by the need for supervised treatments for chronic diseases.
• Biologics & biosimilars are the fastest-growing segment.

By Distribution Channel:

• Hospital pharmacies account for around 26% share, thanks to integrated healthcare services and patient trust.
• Online pharmacies are expanding quickly, especially in metro cities.

Others Report:

https://futuremarketstudies.blogspot.com/2025/08/future-of-gcc-dates-market.html

Recent Developments:

• Sun Pharma (2025) launched Fexuclue® (Fexuprazan) to treat erosive esophagitis.
• Dr. Reddy’s (2025) entered a strategic partnership with Alvotech to co-develop a biosimilar of Merck’s immunotherapy blockbuster, Keytruda.

Conclusion: India’s Pharma Future

The India pharmaceutical industry forecast (2025–2030) paints a clear picture: growth will be fueled by chronic disease prevalence, expanding pharma exports, sustainable practices, and government support.

But to fully realize the projected USD 92.32 billion opportunity, the industry must overcome regulatory hurdles, pricing pressures, and competitive challenges. Those who adapt by blending innovation, sustainability, and compliance will not only drive profitability but also cement India’s role as a global pharma leader under Vision 2030.